3 completed, 2 recruiting, 1 active not recruiting. 3 Phase 1, 2 Not applicable, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Not applicable | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Completed 2 |
Follow Monocytic Leukemia: new trials by email Literature Review of Monocytic Leukemia trials Research Report on Monocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Halt Aging in Survivors of Blood Cancers Behavioral Coaching Intervention, Virtual Exercise Platform - Hematological Malignancy, Leukemia | Not applicable | Recruiting | University of Nebraska | 180 | 2026-04-09 | 2026-07-01 |
| Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia Venetoclax, Azacitidine, Mitoxantrone - Leukemia, Myeloid Leukemia | Phase 1 | Recruiting | University of Colorado, Denver | 30 | 2024-07-21 | 2026-01-15 |
| Integrated Actionable Aging Assessment for Cancer Patients Pilot Assessment tool IA3-CP with SDoH, Assessment tool IA3-CP without SDoH - Breast Cancer, Hodgkin Lymphoma | Not applicable | Active not recruiting | University of Colorado, Denver | 35 | 2024-03-01 | 2025-09-15 |
| Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation Enasidenib mesylat dose escalation - Leukemia, Leukemia, Myeloid | Phase 1 / Phase 2 | Completed | Tian Yi Zhang | 17 | 2022-01-12 | 2026-09-03 |
| FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia Daratumumab/rHuPH20, FT538, Fludarabine - Acute Myeloid Leukemia, Myeloid Leukemia | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 9 | 2021-11-03 | 2024-10-24 |
| Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients Intravenous (IV) and oral Vitamin C - Lymphoid Leukemia, Myeloid Leukemia | Phase 2 | Completed | Virginia Commonwealth University | 61 | 2018-10-01 | 2023-11-07 |
Leukemia, Monocytic, Acute (6) · Leukemia, Myeloid (6) · Leukemia (4) · Leukemia, Lymphoid (3) · Hodgkin Disease (2) · Multiple Myeloma (2) · Anemia, Refractory, with Excess of Blasts (1) · Breast Neoplasms (1) · Graft vs Host Disease (1) · Hematologic Neoplasms (1) · Kidney Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Prostatic Neoplasms (1) · Urinary Bladder Neoplasms (1)
Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Leukemia, Myeloid, Acute (5) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Hemorrhagic Disorders (2) · Hemostatic Disorders (2) · Leukemia (2) · Lymphoma (2)
Ascorbic Acid (1) · Azacitidine (1) · Cyclophosphamide (1) · Mitoxantrone (1) · Social Determinants of Health (1) · daratumumab (1) · enasidenib (1) · fludarabine (1) · fludarabine phosphate (1) · venetoclax (1)
University of Colorado, Denver (2) · Masonic Cancer Center, University of Minnesota (1) · Tian Yi Zhang (1) · University of Nebraska (1) · Virginia Commonwealth University (1)
United States (6)
Andrew Kent, MD, PhD (1) · Joseph Maakaron, MD (1) · Russell E Glasgow (1) · Tian Yi Zhang, MD (1) · Vijaya Raj Bhatt, MBBS,MS (1) · William B Clark, MD (1)
P50CA244688 (1)